VR Logo

Terns Pharmaceuticals Inc. (TERN) download report

Healthcare | Biotechnology & Pharma Research

Terns Pharmaceuticals Inc. (TERN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Get the Stocks!

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.

IPO Date: 05-Feb-2021

CEO & Director: Mr. Senthil Vel Sundaram

Pres & Head of R&D: Dr. Erin Quirk M.D.

Listing: NASDAQ: TERN

Country: United States

Headquarters: Foster City, CA

Website: https://www.ternspharma.com

Key Facts

Market cap: $60.67 Mln

Revenue (TTM): $1.00 Mln

Earnings (TTM): $-50.59 Mln

Cash: $151.27 Mln

Total Debt: $1.58 Mln

Insider's Holding: 5.58%

Liquidity: Low

52 Week range: $1.45 - 13.77

Shares outstanding: 25,279,300

Stock Performance

Time Period Terns Pharmaceuticals (TERN) S&P BSE Sensex* S&P Small-Cap 600*
YTD-64.92-9.18-19.53
1 month50.30-4.78-9.69
3 months-12.37-9.66-16.90
1 Year-80.050.81-17.67
3 Years--10.335.77
5 Years--11.345.69
10 Years--11.749.74
As on 30-Jun-2022 *As on 01-Jul-2022
AMCs: